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This article describes themake-upandactivities of theTechnicalVaccinationCommittee (CTV) that serves
as theNational Immunization Technical AdvisoryGroup (NITAG) in France. Comprisedof a variety of tech-
nical experts, the CTV makes recommendations concerning vaccination. The committee functions as an
independent expert advisory committee, and its proceedings are conﬁdential, although its recommen-
dations are made public. It helps to make decisions about using new vaccines, as well as re-examining
guidelines for vaccines already in use. It obtains technical expertise from a variety of sources, including
specialized national centres. Although it is not obliged to do so, in most cases, the French government
implements CTV recommendations. Information regarding CTV activities is disseminated through publi-
cations, its website, and letters to health ofﬁcials. Efforts need to be enhanced in order to avoid creating a
gap between the issuing of complex vaccination policies and their understanding by general practitioners
he administration of over 80% of all vaccines.
© 2010 Elsevier Ltd.
Table 1
Composition of the CTV: voting members.
 Three specialists in infectious diseases
 Three pediatricians
 Two microbiologists
 Two specialists in epidemiology and public health
 Two general practitioners
 One immunologist
 One geriatrician
Open access under CC BY-NC-ND license. 
who are responsible for t
. Description, background, and membership
The National Immunization Technical Advisory Group (NITAG)
n France is known as the Comité technique des vaccinations, or the
echnical VaccinationCommittee (CTV). TheCTV is comprisedof 20
ualiﬁed members who represent a range of specialties pertaining
o vaccination (Table 1). The CTV also has ex-ofﬁcio members who
epresent agencies afﬁliated with the Ministry of Health, or other
inistries and various institutions (Table 2).
While ofﬁcial legal documents on the establishment of the CTV
nddeﬁnitionof itsmission exist, there arenoofﬁcialwritten terms
f reference for the committee. On the 27th of December 1985,
Abbreviations: ADIP, Accelerated Development and Introduction Plans; AFSS-
PS, French Sanitary Safety Agency for Health Products; BEH, Epidemiology Weekly
ulletin; CEPS, Evaluation Committee of Health Products; CNAM, National Health
nsurance Fund; CNOM, National Council of Medical Board; CSHPF, High Council of
rance for Public Hygiene; CSMT, Committee for Transmissible Diseases; CTV, Tech-
ical Vaccination Committee; DGS, General Directorate for Health; EURO, World
ealth Organization Regional Ofﬁce for Europe; HAS, High Authority of Health;
CSP, High Council for Public Health; IGAS, General Inspection for Social Affairs;
NPES, Prevention and Health Education National Institute; INVS, Sanitary Surveil-
ance Institute;MA,market authorization; NITAG, National Immunization Technical
dvisory Group; WHO, World Health Organization.
 This article draws inpart upon informationoriginally published as:Daniel Floret,
Immunization: Process of elaborating guidelines and their evolution in France.”
nnals Pharmaceutiques Franc¸aises (2009) 67, 219–223.
∗ Corresponding author at: Hôpital Femme Mère Enfant, Bron, 59 Boulevard Pinel
9 500 Bron, France. Tel.: +33 4 72 12 97 38; fax: +33 4 27 86 92 26.
E-mail address: daniel.ﬂoret@chu-lyon.fr (D. Floret).
 One gynecologist-obstetrician/midwife
 One internist
 One maternal and child welfare physician
 One workplace physician
264-410X © 2010 Elsevier Ltd.
oi:10.1016/j.vaccine.2010.02.032
Open access under CC BY-NC-ND license.  One health economist
 One sociologist
a ministerial order was made to set up the CTV as an indepen-
dent expert advisory committee within the framework of the High
Council of France for Public Hygiene (CSHPF). Several amendments
were made to this ﬁrst order, including the order of 12th Novem-
ber 1997 that describes in detail the CTV mission and membership.
Prior to 1985, other similar entities had made recommendations
on immunization. The oldest recommendation dates from 1822,
when a plague epidemic in Marseille prompted the creation of
High Council for Health. In February 1902, the ﬁrst law relating to
the protection of public health mentioned the creation of hygiene
committees. Themission of the present CTV is deﬁned by aministe-
rial order dated 18 September 2007 [1]. Its responsibilities include:
evaluating scientiﬁc information on advances and perspectives in
vaccination; developing vaccination strategies based on applicable
D. Floret, P. Deutsch / Vaccine
Table 2
Composition of the CTV: ex-ofﬁcio members.
 Two representatives of the Armed Forces Health Services
 The Director-General of the Direction Générale de la
Santé (DGS)
 The Director-General of Social Services
 The Director-General of Education
 The Director-General of Social Security
 The Director of the Direction de la recherche, des études,
de l’évaluation et des statistiques (DREES; the department
responsible for oversight of research, studies, assessments
and statistics)
 The Director-General of Employment
 The Director-General of the Agence franc¸aise de sécurité
sanitaire des produits de santé (AFSSAPS; the agency
responsible for the assessment of health product safety)
 The Director-General of the Institut national de
prévention et éducation à la santé (INPES; the institute
responsible for implementing disease prevention and
health education policy)
 The Director-General of the Institut de veille sanitaire
(INVS; the institute responsible for health surveillance)
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G The President of the Conseil national de l’ordre des
médecins (the committee providing oversight for physician
practice)
pidemiological data; conducting risk-beneﬁt analyses (individual
nd population) and health economics studies on measures under
onsideration; and proposing changes to vaccine guidelines and
aking recommendations for immunization schedule updates.
As expressed in the 2004 public health law, “Vaccination policy
s developed by the Minister of Health who establishes immu-
ization conditions, sets forth necessary guidelines, and publishes
mmunization schedules after consultationwith theHaut Conseil de
a Santé Publique (High Council for Public Health or HCSP)” [2]. Vac-
ination guidelines are thus the responsibility of the government,
hich seeks advice from the HCSP, an authoritative public health
dvisory committee. This organization was established in 2006 as
successor to the Conseil Supérieur d’Hygiène Publique or the Supe-
ior Council for Public Hygiene [3]. The CTVwas originally afﬁliated
ith the Commission de Sécurité Sanitaire (Health Security Commis-
ion of the HCSP) but is now attached to Commission des Maladies
ransmissibles, or Committee for Transmissible Diseases (CSMT) of
he HCSP.
The selection of CTV members is based on expertise. When
here is a vacancy, the HCSP issues a call for experts on its web-
ite (www.hcsp.fr) and through its journal. After receiving letters
f interest, a sub-committee is formed involving the General Direc-
orate for Health (DGS), the French health authority of the Ministry
f Health, to select members (via a closed process). Members of the
TV elect the Chairman. The duration of appointment for commit-
ee members is three years, which is renewable and the number of
erms is unlimited. Members do not receive payment for serving
n the CTV. Provided that the Chairman is not a member of the civil
ervice (usually the case), the Chairman is remunerated for meet-
ngs over which he or she presides. Other members, for example
he authors of reports, can be remunerated as well.
There are a number of ex-ofﬁcio members who represent agen-
ies afﬁliated with the Ministry of Health, or other ministries and
arious institutions. While they do not have voting power, they
o have the right to participate actively in discussions. The infor-
ation provided by two organizations, the INVS (Institut de Veille
anitaire or the Sanitary Surveillance Institute) and the AFSSAPS
Agence Franc¸aise de Sécurité Sanitaire des Produits de Santé or the
rench Sanitary Safety Agency for Health Products), often have a
ajor impact on decisionmaking. Usually, the texts are voted upon
o reach consensus.
The committee is currently being evaluated by the Inspection
énérale des Affaires Sociales (IGAS) or the General Inspection for28S (2010) A42–A47 A43
Social Affairs. This assessment may result in changes to the mem-
bership appointment structure in the next year.
2. Declaration of conﬂicts of interest and the conduct of
meetings
2.1. Declaration of conﬂicts of interest
Routine reporting of any conﬂicts of interest regarding commit-
tee members is a requirement, and the management of conﬂicts
of interest is a major concern. The CTV has a conﬂict of interest
charter, which is coupled with a procedure to assess for conﬂicts
of interest. Possible conﬂicts of interest must be declared annually,
and these declarationsmust be kept up-to-date. At the start of each
meeting, members must disclose any possible conﬂicts of interest
they may have concerning topics on the agenda. The situation for
each CTV member is analyzed before each plenary session by the
Secretariat of the HCSP and possibly by the CTV Chairman as well.
This also applies to members of CTV working groups.
Action is taken if a member has any apparent interests in rela-
tion to a vaccine or intervention to be discussed. The conﬂicts of
interest charter consists of classiﬁcation of potential conﬂicts of
interest based on the AFSSAPS’ classiﬁcation of conﬂicts of interest
[4]. If the conﬂict is classiﬁed as minor (e.g., a person was invited
to a conference where industry paid registration fees and accom-
modation but provided no other beneﬁts or compensation), this
person may participate in debates and votes concerning the rel-
evant topic. If conﬂict of interest concerning a particular topic is
classiﬁed as major, the expert in question is excluded both from
debates and votes pertaining to that topic. For example, an expert
who is a coordinating investigator for clinical trials of a certain vac-
cine would be excluded from debates and votes concerning that
vaccine, or competing vaccines or interventions.
2.2. Conduct of meetings
Members are not required to sign a conﬁdentiality form or
similar kinds of agreement. They are informed, however, that the
content of any CTV proceeding is conﬁdential. Despite the lack of
formal agreements, the expectation of conﬁdentiality is implicit
and respected. The CTV has not yet had time to develop documents
or guidelines as to what its members can disclose to the press.
CTV plenary meetings are held in the conference rooms of the
Ministry of Health building, which also hosts the Secretariat of the
HCSP. The plenary meetings of the CTV are not open to the public
and are reserved for CTV members only. However, non-members
may be invited to attend a particular presentation during themeet-
ing. The CTV is expected to hold eight half-day meetings per year
but in practice, eight meetings are not enough. Supplementary
meetings are usually added, both on a scheduled program basis
and ad hoc basis for exceptional circumstances. In 2008, the CTV
held nine meetings. By the end of 2009, 13 CTV meetings were
held, including four supplementary meetings that had not been
previously scheduled.
TheHighCouncil for PublicHealth (HCSP)was originally created
in order to separatemedical expertise from theGeneral Directorate
for Health (DGS), and following this logic, the CTV became a part of
HCSP. Initially, staff of theDGS’ Ofﬁce of Infectious Risks and Immu-
nization Policy (the RI1 ofﬁce: Bureau Risque Infectieux 1), along
with the Secretariat of HCSP, was in charge of coordinating CTV
meetings. This arrangement was changed in June 2009, and now,
the Secretariat of the HCSP is entirely devoted to overseeing this
task, with help provided by an executive secretary and assistant
secretary. They prepare and coordinate the work and meetings of
the CTV in collaboration with the Chairman. A core group is being
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ormed, including theChairman, executive secretary, and twoother
ommittee members, which will be in charge of screening all refer-
als and deciding upon the next steps such as the formation of a
orking group. As the CTV is afﬁliated to theHCSP, it has no speciﬁc
udget.
. Scope of the CTV work and setting the agenda
The committee’s work addresses several related topics within
he scope of vaccines and immunization. Among them is deci-
ion making on the use of new vaccines (e.g., vaccinations
gainst human papillomavirus (HPV) and meningococcus C are
ecommended, while universal vaccinations against chickenpox,
otavirus, and shingles are not). The committee also makes rec-
mmendations concerning vaccination schedules, as in a recent
elf-referral to the CTV to establish guidelines for the simpliﬁ-
ation of immunization schedules, as well as recommendations
n vaccines for high-risk groups such as immuno-suppressed
atients. It makes recommendations on vaccines for other vaccine-
reventable diseases (e.g., re-examination of guidelines for use
f the heptavalent pneumococcal conjugate vaccine, or deﬁning
he conditions of use for a pre-pandemic vaccine). Other recom-
endations concern vaccine formulations, such as the decision
o not replace the trivalent MMR vaccine with the quadrivalent
MR-Varicella, as well as recommendations on the use of speciﬁc
accines for the same disease such as the meningococcal B vaccine.
The CTV sets its agenda or program of work based on sugges-
ions from various sources, including the DGS and pharmaceutical
ompanies. The DGS refers any problems to the CTV that it identi-
es as being concerned with public health and vaccination. The
ompanies inform the CTV when they are awarded marketing
pproval for a new vaccine or in the event of modiﬁcation of a
revious registration. The CTV can also decide to independently
ropose recommendations on issues that it thinks need consider-
tion. However, this must be validated by an HCSP committee. To
e considered for validation, a document must deﬁne the proce-
ures and responsibilities for the working group (nomination of
he chairman, membership make-up, functioning, production, and
ublication of guidelines), while another document outlines the
rocedures to be undertaken when a referral is received by the
TV, as well as an estimated timeline of expected deliverables.
Pharmaceutical companiesmayhave a say in setting the agenda.
s soon as a vaccine has obtained market authorization (MA), the
wner of the MA can submit a dossier to the CTV in order to initi-
te the process of establishing guidelines on vaccine use. Granting
he MA and establishing guidelines are separate procedures with
ifferent endpoints. The MA is granted by the AFSSAPS following
n assessment of the efﬁcacy and safety of the vaccine. Currently,
egistration procedures are European-based. Any possible guide-
ines for vaccine use are established after the MA is obtained, with
he main criterion being the impact of the new product on public
ealth. This type of procedure is not limited to new products; it
ay also be applied when new data on an existing vaccine show a
hange in its impact, thus affecting guidelines on its use.
. Development of recommendations and basis for decision
aking
Sources of technical data and expertise available to the com-
ittee include ofﬁcial CTV members, national centres of expertise,nvitedadhocexperts fromwithin the country,WHOposition state-
ents, and working groups.
A referral made to the CTV concerning a particular topic usu-
lly leads to the creation of a dedicated working group that is
esponsible for investigating the topic. Separate working groupse 28S (2010) A42–A47
are established to look at speciﬁc issues. The groups are a priori ad
hoc but can be reactivated on as-needed basis (e.g., when reconsid-
ering a recommendation based on new data). Certain groups (such
as those concerned with meningococcus and inﬂuenza) are, in fact,
permanent working groups due to their topical nature. There are
no terms of reference for working groups.
When a referral is received, the CTV Chairman establishes a
working group and proposes a working group chairman. The CTV
Chairman then sends the chairman of the working group a lettre
de mission or mission statement, which deﬁnes the ﬁelds of exper-
tise needed, provides details on the delivery of the report, and may
also propose a work plan. The working group chairman and the
executive secretary select members of the working group, desig-
nate a rapporteur when needed, and establish the work schedule.
Tasks are distributed among members according to their exper-
tise or specialization. The rapporteur or chairman of the working
group synthesizes the data collected by the members, develops
the report, and drafts the recommendations. The Secretariat of the
HCSP ensures that the necessary administrative functions are pro-
vided.
The recommendations developed by theworking group are pre-
sented to the larger CTV. The committee assesses the working
group’s recommendations by discussing each of the recommenda-
tions and voting on them throughout multiple plenary meetings.
Additional meetings may be held when an urgent health situation
demands an immediate decision (for example, the recent publica-
tion of data suggesting a possible safety risk for children associated
with the hepatitis B vaccine). In cases where experts disagree over
adoption of a recommendation, they are settled by a majority vote.
Usually, the preliminary discussions make it possible to obtain a
very broad consensus or even unanimity. A slim majority vote or
an elevated level of abstentions will result in further continuation
of work. After an agreement is reached, CTV recommendations are
then transmitted to the CSMT for validation. The CSMT is informed
of the consensus level among the CTV members concerning the
recommendations and may be requested to weigh in.
Working groups receive support on a systematic basis from:
AFSSAPS on questions concerning vaccine safety; the Institut
National de Prévention et Éducation à la Santé (INPES; the institute
responsible for implementation of disease prevention and health
education policy) on issues about communications policy; and the
Institut de Veille Sanitaire (INVS; the institute responsible for epi-
demiological surveillance) for epidemiological issues. Currently,
most CTV investigations consist of pharmaco-epidemiological
studies, as well as disease modeling and assessing different vac-
cination strategies. This disease modeling component is a part of
INVS’ mission; INVS may carry out the modeling itself or assign it
to a public health laboratory of its choice.
There is an opportunity for external members to participate,
with some restrictions, in working groups or in the CTV’s delib-
erations. External experts can be full members of a working group
and may even chair it. They may also be invited to the CTV plenary
meeting to present their reports (if they are chairmanor rapporteur
of the group) or to provide their expertise on a particular issue (for
example, the National Reference Center may present its epidemi-
ological ﬁndings concerning a pathogen). Industry experts cannot
be members of a working group. However, a commercial company
may be heard by the CTV at the request of the CTV or at its own
request. In the case of health economics studies, the company may
be asked to make a presentation to INVS.
The development of a recommendation by the working group
takes intoaccount technological advances associatedwithnewvac-
cines, as well as the evolution of epidemiological characteristics of
diseases in France and elsewhere. International guidelines (notably
those from WHO) are considered, along with an assessment of
the vaccine’s risk-beneﬁt ratio basedonpharmaco-epidemiological
D. Floret, P. Deutsch / Vaccine 28S (2010) A42–A47 A45
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nd modeling studies. Consideration of the organization of health
nd disease prevention systems is also an important element of
he process. In the case of an alert of adverse events following
mmunization or of potential secondary effects, recommendations
ay include requests for strengthened vaccine safety surveillance.
he primary vaccine-preventable outcomes that the CTV uses to
enerate recommendations are, in order of importance: overall
orbidity, mortality, and hospitalizations, as well as epidemic
otential. A referral from the DGS can include a request that out-
omes be given extra consideration in the decisionmaking process.
sually, however, the CTV assembles all of the information avail-
ble in order to reach a decision.
Decision making by the CTV has not required that vaccine cost,
verall program cost, affordability, and ﬁnancial sustainability be
onsidered. Even though the CTV has the authority to contract
xperts to conduct full economic analyses, it has not previously
one so. However, economic studies have been taken into account
or recent decisions (e.g., vaccines against rotavirus and HPV), and
n the future, it is anticipated that most decision making processes
ill need to include an economic evaluation. Therefore, the CTV is
aving discussions with the HAS (Haute Autorité de Santé) on the
ontent and format of these economic evaluations, and will put
nto place a working group to redeﬁne the objectives and measures
f the evaluations (at the moment, the INVS is in charge of eco-
omic evaluations and usually collaborates with a public health
aboratory).
Economicanalyseswere taken into considerationduring the for-
ulation of recommendations for vaccinations against rotavirus,
PV, and meningococcus C. To reach those recommendations, a
ost-beneﬁt analysis was carried out using high and low price esti-
ates of the vaccines. For themeningococcus C vaccine, the current
rice recommended by industry was considered high, while the
rice at which the government had purchased vaccines for previ-
us vaccination campaigns was low. For the rotavirus vaccine, the
hosen price for analysis was the current price recommended by
ndustry. This raised a major issue since after recommendation of
he vaccine is made, the vaccine price is negotiated between gov-
rnment and industry. Therefore, the changing price of the vaccineking process.
means itprobably shouldnotbeconsidered in theeconomicevalua-
tion. This point is currently beingdiscussedwith theHAS. Economic
analyses take a few months to complete, which delays decision
making and prevents the CTV from fulﬁlling its time commitment
to private companies. Economic analyses conducted in other coun-
tries can be taken into account but are not usually considered
sufﬁcient evidence upon which to base a decision. Economic stud-
ies undertaken by the pharmaceutical industry can also be taken
into consideration but they are not considered sufﬁcient. The cur-
rent approach is to compare economic models during the period
prior to reaching a decision.
5. Roles of the CTV and other key players in the decision
making process
Once validated by the Committee for Transmissible Diseases
(CSMT), the recommendations are published on the HCSP web-
site and sent to the Minister of Health, who ultimately decides
whether the CTV recommendations will be incorporated into the
new vaccination schedule (Fig. 1). The vaccination schedules are
updated annually and published in the ofﬁcial bulletin of the Min-
istry of Health. They are then published in the special annual issue
of the Bulletin Épidémiologique Hebdomadaire (BEH; a weekly epi-
demiological bulletin published by INVS), the bulletin of the Conseil
National de l’Ordre des Médecins (CNOM; the main professional
organization for physicians), the bulletin of the Comité d’Éducation
Sanitaire et Sociale de la Pharmacie Franc¸aise (the Permanent Com-
mittee of the National Order of Pharmacists), the Vidal (French
dictionary of pharmaceuticals), and other medical media, as well
as in children’s health textbooks.
When a vaccine has been recommended by CTV, the Commis-
sion for Transparency, which is a part of HAS, evaluates the impact
of the administration of this vaccine on public health services (e.g.,
increase in renderedmedical services). This evaluationwill be used
to determine the level of reimbursement (usually 65%) and will
serve as a basis for negotiation of the vaccine’s price between the
vaccine manufacturer and the CEPS (Comité Economique des Pro-
duits de Santé or Health Products Evaluation Committee). Then the
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overnment will decide whether or not the new recommendation
ill be integrated into the French immunization schedule.
The French government is not obliged to implement the CTV
ecommendations, although it has previously implemented most
f them. Currently, vaccines recommended for the general popula-
ion are subject to reimbursement. Some vaccines recommended
or targeted use are not subject to reimbursement (e.g., hepatitis A
accine for travellers or chickenpox vaccine for adolescents). The
inistry of Finance also plays a role in the decision making but the
xtent of its inﬂuence is unclear to many.
TheCaisseNationaled’AssuranceMaladie (CNAM), or theNational
ealth Insurance Fund, is a public-sector organization and is repre-
entedby ex-ofﬁciomembersof theCTV. TheCNAMisamajorplayer
ince it provides reimbursements for vaccines (seasonal ﬂu vac-
ines, as well as vaccines against measles, mumps and rubella) but
t does not interfere with the decision making process. Professional
rganizations generally do not play any role in the CTV decision
aking process, apart from the CNOM (Conseil National de l’Ordre
es Médecins), the main professional organization for physicians
hat is represented by ex-ofﬁcio members of the CTV.
Pharmaceutical companies do not play any ﬁnancial role in the
TV decision making process even though representatives may be
nvited to make speciﬁc presentations at the discretion of the com-
ittee. Once a year, the CTV holds a speciﬁc meeting during which
ndustry representatives are formally invited to present their activ-
ties; this allows the CTV to remain up-to-date about advances in
he private sector. Special interest or lobbying groups do not pro-
ide any funding or other resources, nor do they intervene in the
ecision making process.
Two contrasting examples of decisionmaking by the committee
llustrate the gap between the committee’s recommendations and
he ultimate decisions that were put into place. The ﬁrst example
oncerns HPV vaccination. The Ministry of Health and the media
xerted pressure on the CTV by publicly announcing that there
ould be reimbursement of the HPV vaccine before the CTV issued
ts opinion. The difﬁculty in assessing the vaccine’s cost-beneﬁt sta-
us and target populations prompted the CTV to seek an economic
valuation and to decline on issuing its full recommendations by
he requested date (rather, it issued limited recommendations con-
erning screening by cervical smear). Its ﬁnal opinion was issued
few months later. However, media coverage of the HPV vaccine
as very strong, and somepeople even considered it excessive. This
ubsequently led to vaccinations being overwhelmingly adminis-
ered to the “catch-up” bracket group (women aged 15–23 years),
ith very little allocated to cover vaccinations for the targeted
ohort group (girls under 14 years of age).
The other example concerns the meningococcus C vaccine, in
hich this case, therewas no external pressure exerted on the CTV.
he CTV reconsidered previous recommendations that were made
n vaccination campaigns conducted in hyper-endemic areas. The
pidemiological ﬁndings from the areas covered by the vaccination
ampaigns, which were compared with national data, played an
mportant role in the decision making process. An economic eval-
ation resulted in the development of a vaccination strategy that
s based on a single-dose immunization of one-year-old children,
ccompanied by a large “catch-up” effort for children, adolescents,
nd young adults. Thiswas recommended in order to promote herd
mmunity, which can protect infants not targeted by vaccination.
. Communications activitiesIn France, more than 80% of the vaccines are administered by
ainly general practitioners (GPs), as well as private practitioners
nd pediatricians. Thus, a major issue lies in how to disseminate
he recommendations and have them understood and accepted by
hysicians.e 28S (2010) A42–A47
The CTV uses various tools for sharing information on CTV activ-
ities with the medical profession and the public. These include
publications such as the Guide des Vaccinations, vaccination guides
published by the INPES, medical professional meetings such as
those held during European Immunization Week, and the websites
of the HCSP and the Ministry of Health (a DGS site speciﬁc to vac-
cination is a work in progress). Other communications tools may
also include letters from the committee to public health ofﬁcials
and physicians. Most CTV members are involved in training activ-
ities on immunization practices, even though this is not a part of
CTV’s mission.
The CTV’s recommendations are made public, as well as the
reports of its working groups. The validated recommendations are
published on the HCSP website and in the special annual issue of
the Bulletin épidémiologique hebdomadaire (BEH; aweekly epidemi-
ological bulletin published by INVS). Theminutes from theworking
group meetings and plenary meetings are not made public. In cer-
tain cases, a letter is sent to the DGS from the CTV Chairman but
this letter is not made public either.
The vaccination schedule is published in several bulletins, such
as the BEH, the CNOM and professional journals. Certain infor-
mation on vaccines is also disseminated by CNAM, the National
Health Insurance Fund. Finally, private companies are permit-
ted to publicize their vaccines. The law no. 2009-879 of the
21st of July 2009 [5] states that companies are authorized to
publicize their vaccines and that they must include a mini-
mum number of sentences in all of their advertisements, which
must be written by the CTV and validated by the HCSP and the
AFSSAPS.
The CTV members communicate among themselves via meet-
ings and e-mails. Working group members communicate via
meetings or conference calls. The HCSP intranet portal, though
active, is not currently used as a means of communication among
CTV members. The CTV does not share information with other
national expert committees.
7. Challenges, limitations, and future developments
Recently, the CTV and the HCSP had to deal with the inﬂuenza
pandemic crisis. This experience has clearly demonstrated the
credibility of their expertise and the impact of their recommen-
dations. However, among the problems experienced by the CTV
was a lack of funding since the scarcity of resources in the Sec-
retariat also limits activities of the committee. Another problem
was the lack of truly independent committee members, as it was
virtually impossible to recruit members that were completely
free from links with industry. However, this was balanced by
employing strong, evidenced-based decision-making procedures,
reducing the risk of inﬂuence and the associated loss of cred-
ibility. Finally, external expertise was hampered by the limited
availability of inﬂuenza experts. During the current crisis linked
to the pandemic ﬂu, CTV experts have been and remain strongly
committed to their home institutions, rendering them somewhat
unavailable to examine the majority of issues addressed by the
CTV.
The evidenced-based decision-making process of the commit-
tee could be further improved by clarifying the positions of the
CTV and the HAS, especially when it comes to the conduct of eco-
nomic evaluations. Additionally, it would be useful to clarify the
positions of experts in relation to their original institutions, includ-
ing the development of policy concerning their payment. Indeed,
most members (including government ofﬁcials) are not paid for
their work with the CTV. This situation might be made more equi-
table if they could work ofﬁcially for the CTV for a certain number
of days per month and be reimbursed through their institutions by
the DGS or the HCSP.
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Some future changes to the committee are in the pipeline, and
hey include improving the understanding of vaccine guidelines,
hich are often unknown or misunderstood by health care profes-
ionals, despite numerous communications efforts using various
eans. In response to a DGS initiative, a strategic committee was
ormed to examine the issue of improving vaccination coverage.
ther measures might be proposed, such as opening CTV plenary
eetings to civil society or holding press conferences following the
elease of new and important recommendations.
. Conclusion
As part of the deployment of the HCSP, the decisionmaking pro-
ess for vaccine-related recommendations was recently revised in
rance. Although the process may seem complex, its purpose is
o guarantee high-quality, independent, and transparent expertise.
he signiﬁcanceof theprocesswas recently recognizedby theWHO
egional Ofﬁce for Europe (WHO EURO), since HCSP was asked to
resent about the CTV organization and its work at the WHO EURO
eeting in Istanbul, Turkey in 2008 [6].
The current dilemma is how to avoid creating and widening
he gap between the increasingly complex process of formulating
accine policy and the implementation of that policy by general
ractitioners, for whom vaccination is not a primary issue despite
he fact that theyadministermore than80%of all vaccines inFrance.
f a solution to this problem cannot be found, new immunization
uidelines may not be translated into daily vaccination practice.
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